<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804050</url>
  </required_header>
  <id_info>
    <org_study_id>EPO2006-AISSM04</org_study_id>
    <secondary_id>2006-006482-16</secondary_id>
    <nct_id>NCT00804050</nct_id>
  </id_info>
  <brief_title>Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts</brief_title>
  <official_title>Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Sindromi Mielodisplastiche Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Sindromi Mielodisplastiche Onlus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized multicenter phase III clinical trial designed to evaluate
      the safety and activity of comparison between Erythropoietin and Erythropoietin Associated to
      Differentiating Therapy With Acid 13-Cis-Retinoic and Dihydroxyvitamin D3 in Myelodysplastic
      Syndromes Without Excess of Blasts
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties of enrollment
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>study of comparison between standard theraphy rEPO (40.000unit/week) and association therapy between rEPO (40.000unit/week)plus Acid 13-Cis-Retinoic and Dihydroxyvitamin D3</measure>
    <time_frame>After 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TO evaluate if,the patients without eritroyd response at the end of the 4° month of therapy, the increase of dose of rEPO to 80.000 U / week allows to get an increase of valued response at the end of the 8° month.</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate if there is a difference of duration in the eritroyd response with standard therapy rEPO in comparison with association therapy rEPO plus Acid 13-Cis-Retinoic and Dihydroxyvitamin D3.</measure>
    <time_frame>20 mounths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the existing relationships among eritroyd response and clinical-biological parameters at baseline of anemia, subclass of MDS, silky dosing of the EPO etc.</measure>
    <time_frame>20 mounths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the quality of life improvement due to therapy.</measure>
    <time_frame>8 mounths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage of leukemic progression.</measure>
    <time_frame>20 mounths</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Infusion A: rEPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rEPO for 4 mounths consequently</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusion B combined r-EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion A: rEPO</intervention_name>
    <description>rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.</description>
    <arm_group_label>Infusion A: rEPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B Infusion rEPO combined with vitamins pills</intervention_name>
    <description>rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3</description>
    <arm_group_label>Infusion B combined r-EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age higher than 18;

          2. Confirmed diagnosis by osseous biopsy and bone marrow cyto-morphologic counts of blast
             cells, of Myelodysplastic syndrome without excess of blasts: &quot;refractary anemia&quot;,
             &quot;refractary anemia with rings sideroblasts&quot;, &quot;refractary citopenya with multilineage
             dysplasia&quot;, &quot; refractary citopenya with multilineage dysplasia and rings sideroblasts&quot;
             or &quot;5q-syndrome&quot; without excess of blasts based on WHO classification (appendix).

          3. Low or intermediate-1 IPSS (appendix).

          4. Hb &lt; 11g/dl.

          5. rEPO serum level &lt; 500mU/L.

          6. Women in menopause from at least one year.

          7. Informed consent

        Exclusion Criteria:

          1. Myelodisplastic syndrome with excess of blasts (RAEB).

          2. IPSS score intermediate-2 or high (appendix).

          3. Forecasted allogeneic bone marrow transplant within 1 year after diagnosis(patients
             younger than 60 years, transfusion dependents or with serious leuko/thrombocytopenia
             and HLA compatible family donor).Considering the time needed to perform this
             procedure, the indication of a transplant from non-consanguineous donor has no
             contraindication to the inclusion in this protocol of the response to rEPO therapy ±
             differentiating therapy.

          4. Renal failure with creatininemia value greater than 3 times the normal limit.

          5. Chronic hepatophaty with bilirubinemia value greater than 3 times the normal limit
             and/or AST or ALT or ALP values greater than 5 times the normal limit.

          6. Presence of second tumor or other serious pathology with life expectancy lower than
             one year.

          7. Presence of neurologic or psychiatric pathologies that make the patient unreliable in
             the acquisition of drugs.

          8. Allergy/intolerance known to use drugs.

          9. Pregnant women.

         10. Women of childbearing age or in menopause from less than one year.

         11. Age &lt; 18 years old.

         12. HIV positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario Ferrero, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Torino - Ospedale San Giovanni Battista</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Levis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale SS. Antonio, Biagio e Cesare Arrigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale SS. Antonio, Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito</name>
      <address>
        <city>Casale (AL)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Chieri (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico dell'Annunziata</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Fano (PU)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile</name>
      <address>
        <city>Ivrea (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Ovada (AL)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinale Panico</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dario Ferrero, MD</name_title>
    <organization>University of Torino - Ospedale S Giovanni Battista</organization>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Acid 13-Cis-Retinoic</keyword>
  <keyword>Dihydroxyvitamin D3</keyword>
  <keyword>low or intermediate-1 IPSS</keyword>
  <keyword>MDS low risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

